Background
Methods
Patients
Assessments
Statistical analysis
Results
Relations between EGFR, KRASstatus and clinicopathological features
Characteristics | Total | No. of patients | |||||
---|---|---|---|---|---|---|---|
EGFRstatus |
p
a
|
KRASstatus |
p
a
| ||||
Mutation | Wild-type | Mutation | Wild-type | ||||
(n = 388) | (n = 185, 47.7%) | (n = 203, 52.3%) | (n = 33, 8.5%) | (n = 355, 91.5%) | |||
Mean age, yr ± SD
b
| 66.6 ± 10.0 | 65.1 ± 10.3 | 67.9 ± 9.57 | 0.462 | 68.6 ± 9.11 | 66.4 ± 10.1 | 0.553 |
Gender | <0.001 | 0.552 | |||||
Male | 228 | 75 | 153 | 21 | 207 | ||
Female | 160 | 110 | 50 | 12 | 148 | ||
Histological type | <0.001 | 0.059 | |||||
Adenocarcinoma | 302 | 183 | 119 | 30 | 272 | ||
Others | 86 | 2 | 84 | 3 | 83 | ||
Vascular invasion | |||||||
Ly - | 314 | 155 | 159 | 0.172 | 25 | 289 | 0.429 |
Ly + | 74 | 30 | 44 | 8 | 66 | ||
V - | 261 | 151 | 110 | <0.001 | 23 | 238 | 0.756 |
V + | 127 | 34 | 93 | 10 | 117 | ||
p-stage | <0.001 | ||||||
I | 293 | 155 | 138 | 22 | 271 | 0.217 | |
II / III | 95 | 30 | 65 | 11 | 84 | ||
T-factor | <0.001 | ||||||
T1 | 197 | 114 | 83 | 14 | 183 | 0.316 | |
T2 / 3 | 191 | 71 | 120 | 19 | 191 | ||
Tumor diameter (cm) | 3.03 ± 1.43 | 2.68 ± 0.92 | 3.35 ± 1.71 | <0.001 | 3.46 ± 1.99 | 2.99 ± 1.36 | 0.001 |
N-factor | 0.348 | ||||||
N0 | 322 | 157 | 165 | 29 | 293 | 0.435 | |
N1 / 2 | 66 | 28 | 38 | 4 | 62 | ||
Smoking status | <0.001 | 0.107 | |||||
Non-smoker | 157 | 106 | 51 | 9 | 148 | ||
Smoker | 231 | 79 | 152 | 24 | 207 | ||
Pre-existing cardiopulmonary comorbidity | 203 | 86 | 117 | 0.028 | 20 | 183 | 0.319 |
Relations between age group and clinicopathological features
No. of patients | ||||
---|---|---|---|---|
Characteristics | Total | ≥80 years | <80 years |
p
a
|
(n = 388) | (n = 29, 7.5%) | (n = 359, 92.5%) | ||
Mean age, yr ± SD
b
| 66.6 ± 10.0 | 82.6 ± 2.41 | 65.3 ± 9.29 | <0.001 |
Gender | 0.246 | |||
Male | 228 | 20 | 208 | |
Female | 160 | 9 | 151 | |
Histology | 0.034 | |||
Adenocarcinoma | 302 | 18 | 284 | |
others | 86 | 11 | 75 | |
Biomarker | ||||
EGFR wild type | 203 | 22 | 181 | 0.008 |
EGFR mutation | 185 | 7 | 178 | |
KRAS wild type | 355 | 23 | 332 | 0.014 |
KRAS mutation | 33 | 6 | 27 | |
Vascular invasion | ||||
Ly - | 314 | 26 | 288 | 0.214 |
Ly + | 74 | 3 | 71 | |
V - | 261 | 18 | 243 | 0.535 |
V + | 127 | 11 | 116 | |
p-stage | 0.080 | |||
I | 293 | 18 | 275 | |
II / III | 95 | 11 | 84 | |
T-factor | 0.506 | |||
T1 | 197 | 13 | 184 | |
T2/3 | 191 | 16 | 175 | |
Tumor diameter (cm) | 3.03 ± 1.43 | 3.00 ± 1.44 | 3.40 ± 1.24 | 0.629 |
N-factor | 0.584 | |||
N0 | 322 | 23 | 299 | |
N1/2 | 66 | 6 | 60 | |
Operation | 0.155 | |||
Limited resection (wedge/segmentectomy) | 80 | 3 | 77 | |
Standard surgery (lobectomy, pneumonectomy) | 308 | 26 | 282 | |
Lymph node resection | <0.001 | |||
ND0/1/sampling | 109 | 25 | 156 | |
ND2 | 278 | 4 | 203 | |
Smoking | 0.024 | |||
Non-smoker | 157 | 6 | 151 | |
Smoker | 231 | 23 | 208 | |
Pre-existing cardiopulmonary comorbidity | 203 | 21 | 182 | 0.024 |
No. of patients | |||
---|---|---|---|
EGFRmutations | Total | ≥80 years | <80 years |
Exon 19 | 73 | 3 | 70 |
Exon 20 | 13 | 0 | 13 |
Exon 21 | 97 | 4 | 93 |
Combined | 2 | 0 | 2 |